Orbis Medicines ApS
CVR 42715646 · Private limited company (ApS) · Active · Low risk
Orbis Medicines ApS is a Private limited company (ApS), founded on , based in Frederiksberg. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.1% over the next 12 months, which is 0.1 times the average for Danish companies. 4 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 287.5m and a net result of DKK -136.5m.
Bankruptcy risk for Orbis Medicines ApS
0.1 × the average (1.41%) · higher risk than 38% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 42715646
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (5 years)
- Address
- Nordre Fasanvej 215
2000 Frederiksberg - Municipality
- Frederiksberg
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 2.8m
- Auditor
- EY Godkendt Revisionspartnerselskab
- Audit opted out
- No
Warning signs
| Annual reports filed late | 0 of 4 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 94.6% |
| Current ratio | 1,725% |
| Moves (last 2 years) | 1 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 111 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Gross profit | DKK -114.1m | DKK -51.6m | DKK -25.6m |
| Net profit | DKK -136.5m | DKK -37.0m | DKK -18.7m |
| Equity | DKK 287.5m | DKK 127.0m | DKK 67.5m |
| Total assets | DKK 303.8m | DKK 158.6m | DKK 69.0m |
| Cash | DKK 145.4m | DKK 128.9m | – |
| Short-term debt | DKK 16.3m | DKK 31.6m | – |
| Avg. employees | 17 | 1 | – |
Latest annual report: Reporting class B · auditor's statement: Revisionspåtegning · (venstre underskriver).
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 174 | ||
| 1 Jan 2024 – 31 Dec 2024 | 148 | ||
| 1 Jan 2023 – 31 Dec 2023 | 109 | ||
| 28 Sep 2021 – 31 Dec 2022 | 180 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Søren Sylvester Skjærbæk | ||
| CEO | João Carlos Ribas de Almeida | ||
| Board | Alonso Ricardo Rodriguez | Current | |
| Board | Søren Møller | Current | |
| Board | Morten Døssing | Current | |
| Board | Edward Timothy Mathers | Current | |
| Board | Marco Boorsma | Current | |
| Board | Goran Mikael Dolsten | Current | |
| Board | Morten Døssing | ||
| Board | João Carlos Ribas de Almeida | ||
| Board | Christian Heinis | ||
| Board | Marco Boorsma | ||
| Board | Vanessa Carle | ||
| Board | Marco Boorsma | ||
| Owner (33%) | Forbion Ventures Fund VI Coöperatief U.A. | Current | |
| Owner (33%) | Novo Holdings A/S | Current | |
| Owner (10%) | GF 2022 Global VC S.á r.l. | Current | |
| Owner (100%) | Novo Holdings A/S | ||
| Owner (90%) | Novo Holdings A/S | ||
| Owner (5%) | Christian Heinis | ||
| Owner (50%) | Novo Holdings A/S | ||
| Auditor | EY Godkendt Revisionspartnerselskab | Current | |
| Auditor | DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | Novo Holdings A/S | Current |
The CEOs' other companies
Søren Sylvester Skjærbæk – 12 other companies, of which 1 bankrupt
- LEDBANNER A/S Bankrupt 16 Sep 2010
- ACTAS A/S Active
- Akylox Therapeutics ApS Active
- BIOMEDICOS A/S Compulsorily dissolved
- HyperBio Therapeutics ApS Opløst
- JOMS ApS Active
- Life Science Legal ApS Active
- NSEXPLORER A/S Opløst
- NSGENE A/S Opløst
- RheumaLogics ApS Active
- SOJA ApS Opløst
- UNIKUM Therapeutics ApS Active
João Carlos Ribas de Almeida – 2 other companies
- NMD Pharma A/S Active
- de novo foundry ApS Active
Address history (1 moves)
| Nordre Fasanvej 215, 2000 Frederiksberg | |
| Stærmosevej 12, 7120 Vejle Øst |
Other companies at the same address
- Nordetect ApS Bankrupt
- ACESION PHARMA ApS Active
- AdaptVac ApS Active
- Adcendo ApS Active
- Akylox Therapeutics ApS Active
- Antraka ApS Opløst
- Augustine Therapeutics Denmark ApS Active
- Autocert ApS Active
- Avancert ApS Active
- B4C ApS Active
- BOOST Pharma ApS Active
- Baekmark IP Consult ApS Active
- Betula Capital ApS Active
- BioPhenyx ApS Active
- Biobridge Partners ApS Active
- Biotinia ApS Active
- CMCAssist ApS Active
- CMCGreenhouse ApS Active
- CMCHoldings ApS Active
- CaMaRa ApS Active
- Catalyst Vaccination A/S Active
- Chris Cording Jønsson Holding ApS Active
- DARERL ApS Active
- DFY ApS Active
- DeltaBot ApS Active
Similar companies in Frederiksberg
- Catalyst Vaccination A/S Frederiksberg
- RefuelBio ApS Frederiksberg
- BioMomentum Advisors ApS Frederiksberg
- Oak Mountain Consulting ApS Frederiksberg
- Biotinia ApS Frederiksberg
- Nordic BioVentures ApS Frederiksberg C
- Zevra Denmark A/S Frederiksberg
- BioPhenyx ApS Frederiksberg
- BioSpringbok ApS Frederiksberg
- Epoqe Pharma ApS Frederiksberg
- SJM IP ApS Frederiksberg C
- Pephexia Therapeutics ApS Frederiksberg
Questions and answers about Orbis Medicines ApS
Has Orbis Medicines ApS gone bankrupt?
No, Orbis Medicines ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of Orbis Medicines ApS?
Our model estimates a bankruptcy risk of 0.1% over the next 12 months (low risk), which is 0.1 times the average for Danish companies.
Who is the auditor of Orbis Medicines ApS?
Orbis Medicines ApS most recently used EY Godkendt Revisionspartnerselskab.
When was Orbis Medicines ApS founded?
Orbis Medicines ApS was founded on 28 September 2021.
What is the equity of Orbis Medicines ApS?
Equity was DKK 287.5m according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.